To assess the therapeutic implications of ORMDL2 dysregulation in GBM, we conducted pharmacogenomic analyses was conducted using the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) datasets. This evidence concerns the gene ORMDL2 and cancer.